-transparent.png){kind=logo}
Azthreonam (SQ 26,776) is a synthetic monocyclic beta-lactam antimicrobial agent belonging to the monobactam family (Sykes et al., Nature [London] 291:489-491, 1981), members of which are characterized by having the 2-oxoazetidine-1-sulfonic acid moiety. Azthreonam exhibits a high degree of stability to beta-lactamases and is specifically active against aerobic gram-negative bacteria, including Pseudomonas aeruginosa. Its activity against these organisms was in general equal or superior to that observed with the third-generation cephalosporins, cefotaxime and ceftazidime. Like penicillins and cephalosporins, azthreonam interacts with essential penicillin-binding proteins of gram-negative bacteria. Azthreonam protected mice against experimental infections produced by a range of gram-negative bacteria, exhibiting efficacy comparable to that of cefotaxime and ceftazidime.
R B Sykes, and
D P Bonner, and
K Bush, and
N H Georgopapadakou
December 1981,
The Journal of antimicrobial chemotherapy,
R B Sykes, and
D P Bonner, and
K Bush, and
N H Georgopapadakou
January 1983,
Antimicrobial agents and chemotherapy,
R B Sykes, and
D P Bonner, and
K Bush, and
N H Georgopapadakou
June 1982,
Antimicrobial agents and chemotherapy,
R B Sykes, and
D P Bonner, and
K Bush, and
N H Georgopapadakou
January 1984,
Medicina clinica,
R B Sykes, and
D P Bonner, and
K Bush, and
N H Georgopapadakou
December 1981,
The Journal of antimicrobial chemotherapy,
R B Sykes, and
D P Bonner, and
K Bush, and
N H Georgopapadakou
December 1981,
The Journal of antimicrobial chemotherapy,
R B Sykes, and
D P Bonner, and
K Bush, and
N H Georgopapadakou
December 1981,
The Journal of antimicrobial chemotherapy,
R B Sykes, and
D P Bonner, and
K Bush, and
N H Georgopapadakou
January 1984,
Chemotherapy,
R B Sykes, and
D P Bonner, and
K Bush, and
N H Georgopapadakou
April 1983,
Antimicrobial agents and chemotherapy,
R B Sykes, and
D P Bonner, and
K Bush, and
N H Georgopapadakou
April 1982,
The Journal of antimicrobial chemotherapy,
